Evaluation of Risk Markers Fluctuation During an Initial Therapy with Rosiglitazon in Patients Suffering from Metabolic Syndrome. Biomol Biomed [Internet]. 2009 Nov. 20 [cited 2024 May 2];9(4):320-8. Available from: https://www.bjbms.org/ojs/index.php/bjbms/article/view/2788